HRP20171981T1 - Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti - Google Patents
Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti Download PDFInfo
- Publication number
- HRP20171981T1 HRP20171981T1 HRP20171981TT HRP20171981T HRP20171981T1 HR P20171981 T1 HRP20171981 T1 HR P20171981T1 HR P20171981T T HRP20171981T T HR P20171981TT HR P20171981 T HRP20171981 T HR P20171981T HR P20171981 T1 HRP20171981 T1 HR P20171981T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- pyrazole
- carboxamide
- morpholin
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Claims (19)
1. Spoj, naznačen time, da ima sljedeću formulu:
[image]
u kojoj
R1 je fenil, po potrebi supstituiran halogenom, C1-7-alkil, C3-6-cikloalkil, C1-7-alkoksi, cijano, C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksi skupinom, C1-7-alkoksi supstituiran halogenom ili C1-7-alkoksi supstuiran hidroksi skupinom; ili je piridin-2, -3 ili -4-il-skupina, po potrebi supstituirana halogenom, C1-7-alkil, C3-6-cikloalkil, cijano, C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksilom, C1-7-alkoksi,
C1-7-alkoksi supstituiran halogenom ili C1-7-alkoksi supstituiran hidroksilnom skupinom; ili je pirimidin-2, -4 ili -5-il-skupina, po potrebi supstituirana halogenom, C1-7-alkil, C3-6-cikloalkil, C1-7-alkil supstituiran hidroksi skupinom ili C1-7-alkil supstituiran halogenom; ili je pirazin-2-il-skupina, po potrebi supstituirana halogenom, C1-7-alkil, C3-6-cikloalkil, C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksi ili cijano skupinom; ili je
2,2-difluorobenzo[d][l,3]dioksol-5-il ili tiazolil po potrebi supstituiran s
C1-7-alkilom koji je supstituiran halogenom;
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
2. Spoj formule IA prema patentnom zahtjevu 1, naznačen time, da je to:
[image]
gdje
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
R4 je vodik, halogen, C1-7-alkil, C3-6-cikloalkil, C1-7-alkoksi, cijano,
C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksilom,
C1-7-alkoksi supstituiran halogenom ili C1-7-alkoksi supstituiran hidroksi skupinom;
n je 1 ili 2;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
3. Spoj prema bilo kojem od zahtjeva 1 ili 2, naznačen time, da su spojevi sljedeći:
(S)-5-metil-N-(4-(morfolin-2-il)fenil)-1-fenil-1H-pirazol-4-karboksamid;
(S)-5-amino-1-(4-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-metoksifenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-cijanofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(R)-1-(4-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-cijanofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-bromo-2-cijanofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-(difluorometoksi)fenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-(difluorometoksi)fenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-cijano-2-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-cijano-3-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(2-cijano-4-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfolin-2-il)fenil)-1-(4-(trifluorometoksi)fenil)-1H-pirazol-4-karboksamid;
(R)-1-(4-(difluorometoksi)fenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-(difluorometoksi)fenil)-5-metil-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-(difluorometoksi)fenil)-3-metil-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(4-cijanofenil)-5-metil-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(R)-1-(4-cijano-2-fluorofenil)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(RS)-1-(4-difluorometoksi-fenil)-1H-pirazol-4-karboksilna kiselina-
(4-pirolidin-3-il-fenil)-amid; ili
(RS)-1-(4-difluorometoksi-fenil)-1H-pirazol-4-karboksilna kiselina-
(4-piperidin-3-il-fenil)-amid.
4. Spoj formule IB prema patentnom zahtjevu 1, naznačen time, da je to:
[image]
gdje
[image]
je piridin-2, -3 ili -4-il-skupina;
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
R5 je vodik, halogen, C1-7-alkil, C3-6-cikloalkil, cijano, C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksi skupinom,
C1-7-alkoksi, C1-7-alkoksi supstituiran halogenom ili C1-7-alkoksi supstituiran hidroksi skupinom;
n je 1 ili 2;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da su spojevi sljedeći:
(S)-1-(5-kloropiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-cijanopiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-bromopiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-jodopiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-morfolin-2-il)fenil)-1-(5-(trifluorometil)-piridin-2-Il)-1H-pirazol-4-karboksamid;
(S)-N-(4-morfolin-2-il)fenil)-1-(4-(trifluorometil)-piridin-2-Il)-1H-pirazol-4-karboksamid;
(S)-1-(4-kloropiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(2-bromopiridin-4-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(6-metoksipiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-fluoro-5-(trifluorometil)piridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(2-kloropiridin-4-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(6-etoksipiridin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfolin-2-il)fenil)-1-(2-(trifluorometil)piridin-4-il)-1H-pirazol-4-karboksamid; ili
(S)-N-(4-(morfolin-2-il)fenil)-1-(6-(trifluorometil)piridin-3-il)-1H-pirazol-4-karboksamid.
6. Spoj s formulama IC1, IC2 i IC3 u skladu s patentnim zahtjevom 1,
naznačen time, da su to:
[image]
gdje
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
R6 je vodik, halogen, C1-7-alkil, C3-6-cikloalkil, C1-7-alkil supstituiran halogenom ili C1-7- alkil supstituiran hidroksi skupinom;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da su spojevi sljedeći:
(S)-1-(5-kloropirimidin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfolin-2-il)fenil)-1-(2-(trifluorometil)pirimidin-4-il)-1H-pirazol-4-karboksamid;
(S)-1-(2-kloropirimidin-4-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfon-2-il)fenil)-1-(5-(trifluorometil)pirimidin-2-il)-1H-pirazol-4-karboksamid;
(S)-1-(4-metilpirimidin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfolin-2-il)fenil)-1-(6-(trifluorometil)pirimidin-4-il)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfon-2-il)fenil)-1-(2-(trifluorometil)pirimidin-5-il)-1H-pirazol-4-karboksamid;
(S)-N-(4-(morfolin-2-il)fenil)-1-(4-(trifluorometil)pirimidin-2-il)-1H-pirazol-4-karboksamid; ili
(S)-1-(6-ciklopropilpirimidin-4-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid.
8. Spoj formule ID prema patentnom zahtjevu 1, naznačen time, da je to:
[image]
gdje
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
R7 je vodik, halogen, C1-7-alkil, C3-6-cikloalkil, C1-7-alkil supstituiran halogenom, C1-7-alkil supstituiran hidroksilnom ili cijano skupinom;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
9. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da su spojevi sljedeći:
(S)-N-(4-(morfolin-2-il)fenil)-1-(6-(trifluorometil)pirazin-2-il)-1H-pirazol-4-karboksamid;
(S)-1-(6-metilpirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-metilpirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-kloropirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-cijanopirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(5-kloropirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(6-cijanopirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid;
(S)-1-(3-cijanopirazin-2-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid; ili
(S)-N-(4-(morfolin-2-il)fenil)-1-(5-(trifluorometil)pirimidin-2-il)-1H-pirazol-4-karboksamid.
10. Spoj formule IE prema patentnom zahtjevu 1, naznačen time, da je to:
[image]
gdje
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
11. Spoj prema bilo kojem od zahtjeva 1 ili 10, naznačen time, da spoj je (S)-1-(2,2-dihiorobenzo[d][1,3]dioksol-5-il)-N-(4-(morfolin-2-il)fenil)-1H-pirazol-4-karboksamid.
12. Spoj formule IF prema patentnom zahtjevu 1, naznačen time, da je to:
[image]
gdje
R2 je vodik ili C1-7-alkil;
R3 je vodik, amino ili C1-7-alkil;
Z je veza, -CH2- ili -O-;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
13. Spoj prema bilo kojem od zahtjeva 1 ili 12, naznačen time, da spoj je (S)-N-(4-(morfolin-2-il)fenil)-1-(4-(trifluorometil)tiazol-2-il)-1H-pirazol-4-karboksamid.
14. Postupak proizvodnje spoja formule I u skladu s bilo kojim od zahtjeva 1 do 13, naznačen time, da postupak obuhvaća
cijepanje zaštitne skupine spojeva formule:
[image]
da bi se stvorio spoj formule I:
[image]
i ako je potrebno,
pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli, pri čemu su supstituenti takvi kao što su opisani u zahtjevu 1.
15. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od patentnih zahtjeva 1 do 13, zajedno s farmaceutski prihvatljivim nosačem i/ili pomoćnom tvari.
16. Farmaceutski sastav u skladu s patentnim zahtjevom 15, naznačen time, da obuhvaća spoj prema bilo kojem od patentnih zahtjeva 1 do 13, zajedno s farmaceutski prihvatljivim nosačem i/ili pomoćnom tvari, za uporabu u liječenju depresije, poremećaja anksioznosti, bipolarnog poremećaja, hiperaktivnog poremećaja s manjkom pozornosti (ADHD), poremećaja uzrokovanih stresom, psihotičnih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetičkih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje energije i asimilacije, poremećaja i nepravilnosti kod homeostaze tjelesne temperature, poremećaja spavanja i cirkadijalnog ritma, te kardiovaskularnih poremećaja.
17. Spojevi prema bilo kojem od patentnih zahtjeva 1 do 13, naznačeni time, da se upotrebljavaju kao terapeutski djelotvorne tvari.
18. Spojevi prema bilo kojem od patentnih zahtjeva 1 do 13, naznačeni time, da se upotrebljavaju u liječenju depresije, poremećaja anksioznosti, bipolarnog poremećaja, hiperaktivnog poremećaja s manjkom pozornosti (ADHD), poremećaja uzrokovanih stresom, psihotičnih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetičkih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje energije i asimilacije, poremećaja i nepravilnosti kod homeostaze tjelesne temperature, poremećaja spavanja i cirkadijalnog ritma, te kardiovaskularnih poremećaja.
19. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1 do 13, naznačena time, da je za proizvodnju lijekova za terapeutsko i/ili profilaktičko liječenje depresije, poremećaja anksioznosti, bipolarnog poremećaja, hiperaktivnog poremećaja s manjkom pozornosti (ADHD), poremećaja uzrokovanih stresom, psihotičnih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetičkih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje energije i asimilacije, poremećaja i nepravilnosti kod homeostaze tjelesne temperature, poremećaja spavanja i cirkadijalnog ritma, te kardiovaskularnih poremećaja.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184360 | 2012-09-14 | ||
| PCT/EP2013/068769 WO2014041007A1 (en) | 2012-09-14 | 2013-09-11 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease |
| EP13759754.8A EP2895477B1 (en) | 2012-09-14 | 2013-09-11 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171981T1 true HRP20171981T1 (hr) | 2018-02-09 |
Family
ID=47044779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171981TT HRP20171981T1 (hr) | 2012-09-14 | 2013-09-11 | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9487501B2 (hr) |
| EP (1) | EP2895477B1 (hr) |
| JP (2) | JP2015531782A (hr) |
| KR (1) | KR101706486B1 (hr) |
| CN (2) | CN107903251A (hr) |
| AR (1) | AR092537A1 (hr) |
| AU (1) | AU2013314388B2 (hr) |
| BR (1) | BR112015004511B1 (hr) |
| CA (1) | CA2882821C (hr) |
| CL (1) | CL2015000580A1 (hr) |
| CR (1) | CR20150087A (hr) |
| DK (1) | DK2895477T3 (hr) |
| EA (1) | EA026062B1 (hr) |
| ES (1) | ES2654653T3 (hr) |
| HK (2) | HK1206720A1 (hr) |
| HR (1) | HRP20171981T1 (hr) |
| HU (1) | HUE037689T2 (hr) |
| IL (1) | IL237332B (hr) |
| LT (1) | LT2895477T (hr) |
| MA (1) | MA37944B2 (hr) |
| MX (1) | MX363362B (hr) |
| MY (1) | MY178667A (hr) |
| NO (1) | NO2895477T3 (hr) |
| NZ (1) | NZ705154A (hr) |
| PE (1) | PE20150735A1 (hr) |
| PH (1) | PH12015500489B1 (hr) |
| PL (1) | PL2895477T3 (hr) |
| PT (1) | PT2895477T (hr) |
| RS (1) | RS56747B1 (hr) |
| SG (1) | SG11201501958QA (hr) |
| SI (1) | SI2895477T1 (hr) |
| TW (1) | TWI610926B (hr) |
| UA (1) | UA113776C2 (hr) |
| WO (1) | WO2014041007A1 (hr) |
| ZA (1) | ZA201501126B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101800594B1 (ko) * | 2014-07-30 | 2017-11-22 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar) 조절제로서 6-아미노-5,6,7,8-테트라하이드로나프탈렌-2-일 또는 3-아미노크로만-7-일 유도체 |
| CN108713019B (zh) * | 2016-03-17 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物 |
| KR20190095355A (ko) * | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
| SG11202110401WA (en) | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| TW202317537A (zh) * | 2021-06-18 | 2023-05-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種malt 1抑制劑及其製備方法和用途 |
| CN116236478A (zh) * | 2022-12-27 | 2023-06-09 | 浙江大学 | 芳香杂环甲酰胺类化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| TW201236685A (en) * | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-09-11 HU HUE13759754A patent/HUE037689T2/hu unknown
- 2013-09-11 RS RS20171358A patent/RS56747B1/sr unknown
- 2013-09-11 DK DK13759754.8T patent/DK2895477T3/en active
- 2013-09-11 KR KR1020157009118A patent/KR101706486B1/ko not_active Expired - Fee Related
- 2013-09-11 NZ NZ705154A patent/NZ705154A/en not_active IP Right Cessation
- 2013-09-11 WO PCT/EP2013/068769 patent/WO2014041007A1/en not_active Ceased
- 2013-09-11 ES ES13759754.8T patent/ES2654653T3/es active Active
- 2013-09-11 CN CN201711272710.XA patent/CN107903251A/zh active Pending
- 2013-09-11 BR BR112015004511-1A patent/BR112015004511B1/pt not_active IP Right Cessation
- 2013-09-11 CN CN201380047584.1A patent/CN104619700A/zh active Pending
- 2013-09-11 AU AU2013314388A patent/AU2013314388B2/en not_active Ceased
- 2013-09-11 PL PL13759754T patent/PL2895477T3/pl unknown
- 2013-09-11 EP EP13759754.8A patent/EP2895477B1/en active Active
- 2013-09-11 HK HK15107153.1A patent/HK1206720A1/xx unknown
- 2013-09-11 JP JP2015531543A patent/JP2015531782A/ja active Pending
- 2013-09-11 MA MA37944A patent/MA37944B2/fr unknown
- 2013-09-11 MX MX2015002900A patent/MX363362B/es unknown
- 2013-09-11 PT PT137597548T patent/PT2895477T/pt unknown
- 2013-09-11 EA EA201590454A patent/EA026062B1/ru not_active IP Right Cessation
- 2013-09-11 NO NO13759754A patent/NO2895477T3/no unknown
- 2013-09-11 PE PE2015000364A patent/PE20150735A1/es active IP Right Grant
- 2013-09-11 MY MYPI2015000641A patent/MY178667A/en unknown
- 2013-09-11 SI SI201330900T patent/SI2895477T1/en unknown
- 2013-09-11 SG SG11201501958QA patent/SG11201501958QA/en unknown
- 2013-09-11 HR HRP20171981TT patent/HRP20171981T1/hr unknown
- 2013-09-11 CA CA2882821A patent/CA2882821C/en active Active
- 2013-09-11 UA UAA201503288A patent/UA113776C2/uk unknown
- 2013-09-11 LT LTEP13759754.8T patent/LT2895477T/lt unknown
- 2013-09-12 AR ARP130103258A patent/AR092537A1/es not_active Application Discontinuation
- 2013-09-13 TW TW102133263A patent/TWI610926B/zh not_active IP Right Cessation
-
2015
- 2015-02-18 ZA ZA2015/01126A patent/ZA201501126B/en unknown
- 2015-02-19 IL IL237332A patent/IL237332B/en active IP Right Grant
- 2015-02-20 CR CR20150087A patent/CR20150087A/es unknown
- 2015-03-06 PH PH12015500489A patent/PH12015500489B1/en unknown
- 2015-03-09 CL CL2015000580A patent/CL2015000580A1/es unknown
- 2015-03-13 US US14/656,853 patent/US9487501B2/en not_active Expired - Fee Related
- 2015-07-27 HK HK18112341.1A patent/HK1252981A1/zh unknown
-
2017
- 2017-02-22 JP JP2017031116A patent/JP6529998B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151077T1 (hr) | Derivati pirazola | |
| HRP20171981T1 (hr) | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti | |
| MY162461A (en) | Substituted benzamide derivatives | |
| AU2002363176B2 (en) | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) | |
| US8680116B2 (en) | Quinolinone PDE2 inhibitors | |
| PH12013501905A1 (en) | Heterocyclic amine derivatives | |
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| RU2012126989A (ru) | 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2 | |
| RU2017107521A (ru) | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar | |
| JP2009542639A5 (hr) | ||
| JP2019505595A5 (hr) | ||
| PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
| JP2020503302A5 (hr) | ||
| MX378486B (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| JP2020503293A5 (hr) | ||
| JP2017536342A5 (hr) | ||
| JP2024527424A5 (hr) | ||
| SI3149002T1 (en) | 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators | |
| US9273033B2 (en) | Substituted pyridone derivatives as PDE10 inhibitors | |
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| RU2017103943A (ru) | Производные 6-амино-5,6,7,8-тетрагидронафтален-2-ила или 3-аминохроман-7-ила в качестве модуляторов taar | |
| HRP20200044T1 (hr) | Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3 | |
| RU2013123901A (ru) | Производные дигидрооксазол-2-амина | |
| RU2017106928A (ru) | Замещенные производные пиразино[2,1-а]изохинолина для лечения заболеваний цнс | |
| RU2024104260A (ru) | Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией |